Annals of internal medicine
-
Randomized Controlled Trial Clinical Trial
A health system program to reduce work disability related to musculoskeletal disorders.
Musculoskeletal disorders (MSDs) are a frequent cause of work disability, accounting for productivity losses in industrialized societies equivalent to 1.3% of the U.S. gross national product. ⋯ Implementation of the program, offered to the general population, improves short- and long-term work disability outcomes and is cost-effective.
-
Randomized Controlled Trial Clinical Trial
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Patients with chronic obstructive pulmonary disease (COPD) frequently develop exacerbations, leading to major clinical and health resource use ramifications. ⋯ Tiotropium reduces COPD exacerbations and may reduce related health care utilization in patients with moderate to severe COPD.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone.
Substituting part of the dose of l-thyroxine with small but supraphysiologic doses of liothyronine in hypothyroid patients has yielded conflicting results. ⋯ Physiologic combinations of L-thyroxine plus liothyronine do not offer any objective advantage over l-thyroxine alone, yet patients prefer combination treatment.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.
Randomized clinical trials have not yet demonstrated the mortality benefit of smoking cessation. ⋯ Smoking cessation intervention programs can have a substantial effect on subsequent mortality, even when successful in a minority of participants.
-
Randomized Controlled Trial Clinical Trial
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
The Pneumonia Severity Index (PSI) has been advocated as an objective measure of risk stratification to help determine the initial site of treatment for patients with community-acquired pneumonia. ⋯ In selected patients who had community-acquired pneumonia, PSI risk class II and III, and were treated with levofloxacin, outpatient care in the absence of respiratory failure, unstable comorbid conditions, complicated pleural effusions, and social problems was as safe and effective as hospitalization and provided greater patient satisfaction.